EMERGENT BIOSOLUTIONS INC. Revenue from Contract with Customer, Excluding Assessed Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Revenue from Contract with Customer, Excluding Assessed Tax of $234.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $234.30M, a 66.29% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $156.10M, a 29.75% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $148.70M, a 23.63% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $231.10M, a 21.34% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $742.90M, a 28.81% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.04B, a 0.54% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.05B.
- EMERGENT BIOSOLUTIONS INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $1.56B, a 40.63% increase from fiscal 2019.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $234.30M 10-Q · filed 2026-08-06 | $390.40M 10-Q · filed 2026-08-06 | $539.10M derived: sum of 3 quarters · filed 2026-08-06 | $770.20M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $156.10M 10-Q · filed 2026-05-01 | $304.80M derived: sum of 2 quarters · filed 2026-05-01 | $535.90M derived: sum of 3 quarters · filed 2026-05-01 | $676.80M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $148.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $379.80M derived: sum of 2 quarters · filed 2026-02-27 | $520.70M derived: sum of 3 quarters · filed 2026-08-06 | $742.90M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $231.10M 10-Q · filed 2025-10-30 | $372.00M derived: sum of 2 quarters · filed 2026-08-06 | $594.20M 10-Q · filed 2025-10-30 | $788.90M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $140.90M 10-Q · filed 2026-08-06 | $363.10M 10-Q · filed 2026-08-06 | $557.80M derived: sum of 3 quarters · filed 2026-08-06 | $851.60M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $222.20M 10-Q · filed 2026-05-01 | $416.90M derived: sum of 2 quarters · filed 2026-05-01 | $710.70M derived: sum of 3 quarters · filed 2026-05-01 | $965.40M derived: sum of 4 quarters · filed 2026-05-01 | |||
| 2024-12-31 | $194.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $488.50M derived: sum of 2 quarters · filed 2026-02-27 | $743.20M derived: sum of 3 quarters · filed 2026-02-27 | $1.04B 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $293.80M 10-Q · filed 2025-10-30 | $548.50M derived: sum of 2 quarters · filed 2025-10-30 | $848.90M 10-Q · filed 2025-10-30 | ||||
| 2024-06-30 | $254.70M 10-Q · filed 2025-08-07 | $555.10M 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | $300.40M 10-Q · filed 2025-05-08 | ||||||
| 2023-12-31 | $1.05B 10-K · filed 2026-02-27 | ||||||
| 2021-06-30 | $397.50M 10-Q · filed 2021-07-30 | $740.50M 10-Q · filed 2021-07-30 | $1.32B derived: sum of 3 quarters · filed 2021-07-30 | $1.71B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2021-03-31 | $343.00M 10-Q · filed 2021-04-30 | $926.00M derived: sum of 2 quarters · filed 2021-04-30 | $1.31B derived: sum of 3 quarters · filed 2021-04-30 | $1.71B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2020-12-31 | $583.00M 10-K · filed 2021-02-19 | $968.20M derived: sum of 2 quarters · filed 2021-02-19 | $1.36B derived: sum of 3 quarters · filed 2021-07-30 | $1.56B 10-K · filed 2021-02-19 | |||
| 2020-09-30 | $385.20M 10-K · filed 2021-02-19 | $779.90M derived: sum of 2 quarters · filed 2021-07-30 | $972.40M 10-Q · filed 2020-11-06 | $1.33B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2020-06-30 | $394.70M 10-Q · filed 2021-07-30 | $587.20M 10-Q · filed 2021-07-30 | $947.60M derived: sum of 3 quarters · filed 2021-07-30 | $1.26B derived: sum of 4 quarters · filed 2021-07-30 | |||
| 2020-03-31 | $192.50M 10-Q · filed 2021-04-30 | $552.90M derived: sum of 2 quarters · filed 2021-04-30 | $864.70M derived: sum of 3 quarters · filed 2021-04-30 | $1.11B derived: sum of 4 quarters · filed 2021-04-30 | |||
| 2019-12-31 | $360.40M 10-K · filed 2021-02-19 | $672.20M derived: sum of 2 quarters · filed 2021-02-19 | $915.40M derived: sum of 3 quarters · filed 2021-02-19 | $1.11B 10-K · filed 2021-02-19 | |||
| 2019-09-30 | $311.80M 10-K · filed 2021-02-19 | $555.00M derived: sum of 2 quarters · filed 2021-02-19 | $745.70M 10-Q · filed 2020-11-06 | $1.02B derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-06-30 | $243.20M 10-K · filed 2021-02-19 | $433.90M 10-Q · filed 2020-07-31 | $704.50M derived: sum of 3 quarters · filed 2021-02-19 | $878.20M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-03-31 | $190.60M 10-K · filed 2021-02-19 | $461.30M derived: sum of 2 quarters · filed 2021-02-19 | $635.00M derived: sum of 3 quarters · filed 2021-02-19 | $855.20M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2018-12-31 | $270.70M 10-K · filed 2020-02-25 | $444.40M derived: sum of 2 quarters · filed 2020-02-25 | $664.60M derived: sum of 3 quarters · filed 2020-02-25 | $782.40M 10-K · filed 2021-02-19 | |||
| 2018-09-30 | $173.70M 10-K · filed 2020-02-25 | $173.65M 10-Q · filed 2018-11-02 | $393.90M derived: sum of 2 quarters · filed 2020-02-25 | $511.70M 10-Q · filed 2019-11-07 | $511.67M 10-Q · filed 2018-11-02 | $705.50M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $220.20M 10-K · filed 2020-02-25 | $338.00M 10-Q · filed 2019-08-02 | $338.01M 10-Q · filed 2018-08-03 | $531.80M derived: sum of 3 quarters · filed 2020-02-25 | $681.20M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $117.80M 10-K · filed 2020-02-25 | $117.81M 10-Q · filed 2018-05-04 | $311.60M derived: sum of 2 quarters · filed 2020-02-25 | $461.00M derived: sum of 3 quarters · filed 2020-02-25 | $561.80M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $193.80M 10-K · filed 2019-02-22 | $343.20M derived: sum of 2 quarters · filed 2019-02-22 | $444.00M derived: sum of 3 quarters · filed 2019-02-22 | $560.90M 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $149.40M 10-K · filed 2019-02-22 | $149.43M 10-Q · filed 2018-11-02 | $250.20M derived: sum of 2 quarters · filed 2019-02-22 | $367.06M 10-Q · filed 2018-11-02 | |||
| 2017-06-30 | $100.80M 10-K · filed 2019-02-22 | $100.77M 10-Q · filed 2018-08-03 | $217.63M 10-Q · filed 2018-08-03 | ||||
| 2017-03-31 | $116.90M 10-K · filed 2019-02-22 | ||||||
| 2016-12-31 | $488.80M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |